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Systemic glucose homeostasis is primarily regulated by insulin, which targets liver, fat, and skeletal muscle
cells, setting up important feedback loops. New studies now show that the osteoblast also has a significant
role in modulating systemic insulin responses, via the insulin-regulated transcription factor FOXO1 and the
hormone osteocalcin.Insulin is the master regulator of systemic
energy management, via control of glu-
cose metabolism. Although there are
feedback loops for both insulin and glu-
cose, other hormones also play important
roles in modulating insulin levels and
peripheral insulin sensitivity. One well-
established hormone that affects glu-
cose homeostasis, independent of insulin
levels, is adiponectin, which is produced
by adipocytes in white fat. Using ubiqui-
tously expressed receptors, adiponectin
enhances end-organ sensitivity to insulin,
and decreases insulin resistance in high-
fat diet models of metabolic syndrome
(Kubota et al., 2002). That a fat-derived
hormone affects energy usage is not
unexpected. However, the discovery that
osteoblasts (OBs), the cells responsible
for bone formation, also play a critical
role in systemic control of glucose is
surprising. Correlations between levels
of osteocalcin, an OB-specific factor,
and glycemic control were identified 15
years ago (Sayinalp et al., 1995). How-
ever, the mechanism for the interaction
between osteocalcin and blood glucose
has been elucidated only recently. In an
elegant study in The Journal of Clinical
Investigation, Rached et al. (2010) dem-
onstrate that the transcription factor
FOXO1, which is downregulated by insu-
lin, controls the activity of osteocalcin,
thus connecting glucose homeostasis to
the OB.
Although a receptor for osteocalcin still
has not been identified, this molecule
appears to be a bone fide hormone. It is
synthesized exclusively by OBs as a pre-
pro-protein, and secreted into the circula-
tion. Osteocalcin negatively regulates
matrix deposition by OBs, but Ocn/
mice do not have abnormal skeletal
patterning or mineralization (Ducy et al.,
1996). Thus, although osteocalcin hasskeletal effects, it is not a central mediator
of bonehomeostasis. In contrast,Ocn/
mice have very significant changes in glu-
cose homeostasis, with increased blood
glucose and decreased serum insulin
(Lee et al., 2007). Because OBs and fibro-
blasts stimulate insulin production by
pancreaticbcells in coculture, in anosteo-
calcin-dependent manner, it is likely that
osteocalcin directly targets b cells. Osteo-
calcin has many effects on b cells that are
beneficial to glucosehandling. It increases
b cell proliferation, as well as promoting
insulin production and sensitivity. Osteo-
calcin also appears to directly regulate
the production of adiponectin by adipo-
cytes (Lee et al., 2007). Because Osteo-
calcin controls glucose homeostasis by
targeting both pancreatic b cells and
adipocytes, this hormone and the OBs
that secrete it represent interesting poten-
tial therapeutic targets, and further under-
standing of their regulation is of great
interest.
Because the endocrine system is com-
posed of many positive and negative
feedback loops, it seemed likely that
insulin might control osteocalcin levels,
which would then feedback on insulin
levels and sensitivity. FOXO1, a member
of the Forkhead family, is the primary tran-
scription factor mediating insulin effects
in b cells, hepatocytes, and adipocytes.
Insulin signaling decreases FOXO1 activ-
ity, causing its phosphorylation and
nuclear export. Now Rached et al. have
found that, as in other cells, FOXO1 is
a critical mediator of insulin signaling in
osteoblasts. Surprisingly, however, its
targets are two osteoblast-specific tran-
scripts, Ocn, encoding osteocalcin and
Esp, encoding the protein tyrosine phos-
phatase OST-PTP. Via direct binding to
specific DNA recognition sites in these
loci, FOXO1 inhibits expression of OcnCell Metabolismand promotes expression of Esp. Thus,
exposure of OBs to insulin, or removal of
Foxo1 in these cells, increases Ocn and
decreases Esp (Figure 1). Although the
exact mechanism by which the Esp pro-
duct OST-PTP works has not been eluci-
dated, the Karsenty group has demon-
strated that this phosphatase inactivates
osteocalcin by enhancing its g-carboxyla-
tion (Lee et al., 2007). Thus, the net effect
of insulin (or loss of Foxo1) is to enhance
both synthesis of Osteocalcin by OBs
and the activation status of this hormone,
by keeping it in its uncarboxylated state.
The phenotype of OB-specific Foxo1-
deficient (Foxo1ob/) mice was investi-
gated in detail, to determine whether
the activity of this transcription factor in
the OB regulates glucose homeostasis
systemically. Despite the presence of
FOXO1 in b cells, myocytes, hepatocytes,
and adipocytes, Foxo1ob/ mice had
dramatic changes in glucose handling
by these cells. b cell numbers were
increased, basal insulin levels were
higher, and glucose levels were lower,
and animals had improved glucose and
insulin tolerance. In the liver, Foxo1ob/
mice were better able to suppress gluco-
neogenesis than their WT littermates and
had decreased liver fat content, both
indications of improved insulin sensitivity.
Mitochondrial respiratory chain proteins
and ATP production were upregulated in
the muscle of Foxo1ob/ mice, and
overall O2 and CO2 consumption rates
were increased. Interestingly, the only fat
affected in these mice was the gonadal
fat pad, which was decreased in weight
and number of adipocytes, although
individual cells were larger. Expression of
adipogenic and lipogenic genes was
decreased, as expected for enhanced cir-
culating insulin. The most important effect
on adipocytes, however, is probably11, March 3, 2010 ª2010 Elsevier Inc. 175
Figure 1. FOXO1 Modulates Insulin Responses via Osteocalcin
The FOXO1 transcription factor upregulates OST-PTP and downregulates osteocalcin in the osteoblast. Insulin suppresses FOXO1, enhancing osteocalcin
synthesis and decreasing OST-PTP. OST-PTP increases g-carboxylation of osteocalcin, which inactivates this hormone. The net effect of insulin is to increase
active osteocalcin, which then acts on b cells in the pancreas and adipocytes (blue arrows). Osteocalcin stimulates proliferation of b cells, and their insulin produc-
tion and sensitivity. Insulin then acts on hepatocytes, myocytes, and adipocytes, promoting glucose homeostasis. It also inhibits FOXO1 in osteoblasts, creating
an insulin/osteocalcin positive feedback loop. Osteocalcin also increases secretion of adiponectin by adipocytes, which enhances peripheral insulin sensitivity,
further promoting efficient glucose metabolism.
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ing to a 30% increase in serum levels of
this hormone, which controls insulin
sensitivity. Importantly, the improved glu-
cose handling by Foxo1ob/ mice was
prevented by removing one allele of
Ocn, demonstrating the critical role of
osteocalcin in mediating the effects
of FOXO1. Furthermore, the importance
of control of the carboxylation status of
osteocalcin was demonstrated by gener-
ating mice heterozygous for both Foxo1
and Esp, which showed a phenotype
very similar to Foxo1ob/ mice. In sum,
expression of FOXO1 in osteoblasts
affects insulin secretion and systemic
insulin responsivity.
The series of papers from the Kousteni
and Karsenty groups delineating the role
of the OB in glucose homeostasis using
mouse models is supported by several
studies correlating osteocalcin levels
with glucose control in humans (Fuku-
moto and Martin, 2009). One observation
that contradicts this correlation is that
patients with primary hyperparathy-176 Cell Metabolism 11, March 3, 2010 ª201roidism have a predisposition to insulin
resistance (Procopio et al., 2002), in the
face of increased osteocalcin levels
(Reppe et al., 2006). PTH could have
a direct effect on b cells that overrides
the effect of increased osteocalcin, but
this has not been directly studied.
PTH(1-34) (teriparatide), given therapeu-
tically to increase bone mass, stimu-
lates OBs, and increases OB number
when administered in a pulsatile fashion.
Whether glucose handling is improved in
these patients is not known. Because
the activity of OBs is usually coupled to
that of osteoclasts, drugs that target
the latter cell such as bisphosphonates
or anti-RANKL antibodies may affect
OBs sufficiently to alter glucose homeo-
stasis. Based on the newly detailed
mechanism by which osteocalcin impacts
insulin responses, hypothesis-driven pro-
spective human studies should be
designed to determine whether the
interaction between bone and glucose/
insulin can be exploited therapeutically
in humans.0 Elsevier Inc.REFERENCES
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